Why so impartant in Market Access?
“Health technology assessment (HTA) increasingly plays an important role in informing reimbursement and pricing decisions and providing clinical guidance on the use of medical technologies across the world. In addition to safety and efficacy information, health economic and outcomes research data are also receiving expanded attention in these assessments in many countries, due to payers seeking better value for money spent on treatments. HTA is now commonly viewed as a tool to assist evidence-based health-care decisions. It has had various definitions over the years and across countries, but as defined herein, it is the systematic evaluation of a medical or health technology for evidence of its safety, efficacy, effectiveness, cost, cost-effectiveness, and ethical and legal implications, both in absolute terms and in comparison with other competing technologies.” [ source ]
team
an interdisciplinary team consisting of physicians, pharmacists, economists, statisticians and lawyers, in effect substantially correct products
methodology
proven methodology and vast knowledge that we share during the preparation of the report
departments
separate specialist departments (clinical, cost, economical and counseling) is completely focussed on the special orders
We prepare HTA reports for all countries of the region as well as adjust existing reports or models to specific local requirements.
Many outcomes
Clinical analysis
- Effectiveness of therapy
- Safety of therapy
- Critical appraisal of clinical trials
- Critical appraisal of protocols of clinical trials
- Planning of clinical trials
(experimental and observational)
Economic analysis
- Comparison of cost-effectiveness of different technologies
- Value based pricing
- Modelling
- Mean costs of treatment per patient (together with evaluation of cost and clinical consequences of treatment)
Cost analysis
- Cost of illness evaluation
- Evaluation of schemes of treatment
- Identification of differences in costs (complications, adverse events)
- Adaptation of external models
- Social impact of disease
BIA
- Reimbursement strategy
- Prognosis of expenditures of payer, health care providers, manufacturer, patient
- Financial and organizational conditions of reimbursement
- Risk-sharing agreements